Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-05-17

Clinical Trial Update: Pilot Study of Using Copeptin to Predict Response to Tolvaptan [Phase 4]

View source ↗

Summary

A Phase 4 pilot study evaluated copeptin as a predictor of response to tolvaptan in heart failure. Results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • tolvaptan (tolvaptan)

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: Cardiovascular Diseases, Heart Diseases | Phase 4 | Status: COMPLETED | Results posted: 2017-05-17